Image Guidance in Malignant Gliomas: a Focused Strategy

Overview

Journal CNS Oncol

Specialty Oncology

Date 2014 Jul 25

PMID 25057863

Authors

Evangelia Katsoulakis

Kathryn Beal

Yoshiya Yamada

Affiliations

Soon will be listed here.

Abstract

The standard of care for malignant gliomas is maximal surgical cytoreduction followed by concurrent chemoradiation and adjuvant chemotherapy with temozolomide. Chemotherapy adds a modest improvement in overall survival. Unfortunately, tumor recurrence is the rule and typically occurs at the initial site of disease. Salvage reirradiation may be a useful approach in selected patients with recurrent glioblastoma. Image-guided technology coupled with highly conformal treatment planning techniques have allowed the safe delivery of high-dose radiotherapy in the setting of tumor recurrence. Defining the optimal combination of hypofractionated stereotactic radiotherapy with chemotherapy is under investigation. In this perspective, we examine the role of image guidance in malignant gliomas.

References

Cho K, Hall W, Gerbi B, Higgins P, McGuire W, Clark H . Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999; 45(5):1133-41. DOI: 10.1016/s0360-3016(99)00336-3. View

Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y . Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2008; 91(2):199-206. DOI: 10.1007/s11060-008-9699-x. View

Maucort-Boulch D, Baron M, Pommier P, Weber D, Mizoe J, Rochat J . Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials. Cancer Radiother. 2009; 14(1):34-41. DOI: 10.1016/j.canrad.2009.08.141. View

Niyazi M, Siefert A, Schwarz S, Ganswindt U, Kreth F, Tonn J . Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2010; 98(1):1-14. DOI: 10.1016/j.radonc.2010.11.006. View

Henke G, Paulsen F, Steinbach J, Ganswindt U, Isijanov H, Kortmann R . Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol. 2009; 185(2):113-9. DOI: 10.1007/s00066-009-1969-9. View

Kristiansen K, Hagen S, KOLLEVOLD T, TORVIK A, Holme I, Nesbakken R . Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma.... Cancer. 1981; 47(4):649-52. DOI: 10.1002/1097-0142(19810215)47:4<649::aid-cncr2820470405>3.0.co;2-w. View

van Vuurden D, Hulleman E, Meijer O, Wedekind L, Kool M, Witt H . PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011; 2(12):984-96. PMC: 3282104. DOI: 10.18632/oncotarget.362. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

10.

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

11.

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

12.

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

13.

Bujold A, Craig T, Jaffray D, Dawson L . Image-guided radiotherapy: has it influenced patient outcomes?. Semin Radiat Oncol. 2011; 22(1):50-61. DOI: 10.1016/j.semradonc.2011.09.001. View

14.

Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E . Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000; 23(2):155-9. DOI: 10.1097/00000421-200004000-00010. View

15.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

16.

Patel M, Siddiqui F, Jin J, Mikkelsen T, Rosenblum M, Movsas B . Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2008; 92(2):185-91. DOI: 10.1007/s11060-008-9752-9. View

17.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

18.

Tselis N, Kolotas C, Birn G, Roddiger S, Filipowicz I, Kontova M . CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol. 2007; 183(10):563-70. DOI: 10.1007/s00066-007-1721-2. View

19.

Gabayan A, Green S, Sanan A, Jenrette J, Schultz C, Papagikos M . GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006; 58(4):701-9. DOI: 10.1227/01.NEU.0000194836.07848.69. View

20.

Mandl E, Dirven C, Buis D, Postma T, Vandertop W . Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008; 69(5):506-9. DOI: 10.1016/j.surneu.2007.03.043. View